Verifying…
Home / Drug A–Z / Kemi Cream## (strength format)

Kemi Cream## (strength format)

NAFDAC Reg. No. 04-2034 · Drug

Registered with NAFDAC — registration activeAs of 5 November 2026 · synced automatically from official sources.
Product
Kemi Cream## (strength format)
NAFDAC number
04-2034
Active ingredient
Beclometasone; Clotrimazole
Strength
0.00625g; 0.25g
Form
Cream
Pack size
1 x 15 g tube
Manufacturer
Not listed
Applicant (holder)
Jawa International Limited
Approved
28 Sep 2021
Status
Inactive View on NAFDAC ↗
Registration valid to
27 Sep 2026
WHO alerts
None found
Community reports
None
Times checked
0

RxVerify commentary

  • Kemi Cream## (strength format) is on the NAFDAC register with an active registration (04-2034). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. Not medical advice — always follow your doctor or pharmacist.

What Kemi Cream## (strength format) is used for

From the official U.S. FDA label for beclometasone, the active ingredient registered with NAFDAC.

What it is used for

QVAR REDIHALER is indicated in the maintenance treatment of asthma as prophylactic therapy in adults and pediatric patients 4 years of age and older. Limitations of Use: QVAR REDIHALER is not indicated for the relief of acute bronchospasm. QVAR REDIHALER is a corticosteroid indicated for maintenance treatment of asthma as prophylactic therapy in adults and pediatric patients 4 years of age and older. ( 1 ) Limitations of Use : Not indicated for the relief of acute bronchospasm. ( 1 )

Possible side effects

The following clinically significant adverse reactions are described elsewhere in the labeling: Oropharyngeal candidiasis [see Warnings and Precautions ( 5.1 )] Immunosuppression and risk of infections [see Warnings and Precautions ( 5.4 )] Hypercorticism and adrenal suppression [see Warnings and Precautions ( 5.7 )] Reduction in bone mineral density [see Warnings and Precautions ( 5.9 )] Growth effects [see Warnings and Precautions ( 5.8 ) and Use in Specific Populations ( 8.4 )] Glaucoma and cataracts [see Warnings and Precautions ( 5.10 )] Most common adverse reactions (incidence > 3% and > placebo) include oral candidiasis, upper respiratory tract infection, nasopharyngitis, allergic rhi …

Do not use if

QVAR REDIHALER is contraindicated in: the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required [see Warnings and Precautions ( 5.2 )] . in patients with known hypersensitivity to beclomethasone dipropionate or any of the ingredients in QVAR REDIHALER [see Warnings and Precautions ( 5.6 )] . Primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. …

Warnings

Oropharyngeal candidiasis: Candida albicans infection of the mouth and throat may occur. Monitor patients periodically for signs of adverse effects on the oral cavity. Advise patients to rinse the mouth with water without swallowing after inhalation to help reduce the risk. ( 5.1 ) Deterioration of asthma and acute episodes: Do not use QVAR REDIHALER for relief of acute symptoms. Patients require immediate re-evaluation during rapidly deteriorating asthma. ( 5.2 ) Transferring patients from systemic corticosteroids: Risk of impaired adrenal function when transferring from oral steroids. Taper patients slowly from systemic corticosteroids if transferring to QVAR REDIHALER. …

Pregnancy & breastfeeding

IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no adequate and well‑controlled studies with QVAR REDIHALER or beclomethasone dipropionate in pregnant women. There are clinical considerations with the use of inhaled corticosteroids (ICS), including beclomethasone dipropionate, in pregnant women [see Clinical Considerations] . …

General information only — not dosing advice. Always follow the leaflet in your pack and your doctor or pharmacist.

Check your pack of Kemi Cream## (strength format)

Add the expiry date printed on your pack for a full Trust Score — or look up uses, side effects and cheaper generics.

3 free checks left today · no signup Official sources: NAFDAC Green Book & recalls · WHO · U.S. FDA · NLM RxNorm

About Kemi Cream## (strength format)

What is in Kemi Cream## (strength format)?

Kemi Cream## (strength format) contains Beclometasone; Clotrimazole (0.00625g; 0.25g), as cream, according to its NAFDAC registration record.

Is Kemi Cream## (strength format) registered with NAFDAC?

Yes. Kemi Cream## (strength format) is listed on the NAFDAC register under registration number 04-2034, and its registration is active as of 5 November 2026.

Has Kemi Cream## (strength format) been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Kemi Cream## (strength format) in our automatically synced alert list.

How can I check that my pack of Kemi Cream## (strength format) is genuine?

Run a free authenticity scan with the NAFDAC number 04-2034, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

What is Kemi Cream## (strength format) used for?

QVAR REDIHALER is indicated in the maintenance treatment of asthma as prophylactic therapy in adults and pediatric patients 4 years of age and older. Limitations of Use: QVAR REDIHALER is not indicated for the relief of acute bronchospasm. QVAR REDIHALER is a corticosteroid indicated for maintenance treatment of asthma as prophylactic therapy in adults and pediatric patients 4 years of age and old (Summarised from the official U.S. FDA label for beclometasone. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Kemi Cream## (strength format)? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from RxVerify users, not medical advice. Report side effects to your doctor and to NAFDAC.